



Dr. Steve Helmke Appointed Chief Scientific Officer

DENVER (April 15, 2017) -- HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that Dr. Steve Helmke, has been appointed Chief Scientific Officer.

“We are extremely pleased to have Dr. Helmke in this pivotal role at HepQuant,” said HepQuant Founder and Chief Executive Officer Dr. Gregory T. Everson. “He possesses a deep scientific and clinical knowledge of our product set and the legacy research behind our tests.”

In addition to his years directing operations in Dr. Everson’s lab, Dr. Helmke formerly served as Research Instructor in the Gastroenterology Division at the School of Medicine, University of Colorado located at the Anschutz Medical Center in Aurora, CO. He received his undergraduate degree in Biochemical Sciences from Princeton University and his Ph.D. in Biological Chemistry from UCLA before moving to Colorado to pursue a career focused on protein biochemistry and quantitative mass spectrometry. He was involved in the startup of Myogen and directed their first laboratory project, a contract from Lilly to investigate mechanisms of heart failure. He was the lead scientist on a Pfizer sponsored project at the University of Colorado for the screening of new cancer drugs.

Dr. Helmke was a member of the scientific team in Dr. Everson’s laboratory at the University of Colorado that developed and validated quantitative mass spectrometry testing methods for the cholates used in the HepQuant tests. These methods were used in the development of the Disease Severity Index, US Patent #9,091,701. In 2017, Dr. Helmke left the University of Colorado to become the Chief Scientific Officer for HepQuant.

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT

Tom Kennedy, Corporate Communications

Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com